Results 251 to 260 of about 129,703 (302)
Development of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents. [PDF]
Antonijevic M +11 more
europepmc +1 more source
Nuclear Alpha‐Synuclein: Mechanisms and Implications for Synucleinopathies
Abstract Alpha‐synuclein (aSyn), historically studied for its synaptic functions and central role in Lewy body pathology, is emerging as a protein with significant nuclear activities relevant to Parkinson's disease (PD) and related synucleinopathies. Recent advances reveal that aSyn dynamically localizes to neuronal nuclei in both health and disease ...
Tiago Fleming Outeiro, David J. Koss
wiley +1 more source
Anorexigenic neuropeptides as anti-obesity and neuroprotective agents: exploring the neuroprotective effects of anorexigenic neuropeptides. [PDF]
Strnadová V +6 more
europepmc +1 more source
Glaucomatous optic neuropathy management: the role of neuroprotective agents.
Marianne L. Shahsuvaryan
openalex +1 more source
Curcumin as a neuroprotective agent: mechanisms and therapeutic potential in neurodegenerative diseases, acute brain injuries, and neuroinflammation. A review of the literature [PDF]
Żanna Gawrysz +5 more
openalex +1 more source
Uncovering the Complexity of Synucleinopathies: An Ongoing Tale Between Proteins and Lipids
Abstract Neurodegenerative diseases are pathological states characterized by progressive alterations in brain homeostasis during aging. Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are defined neuropathologically by the accumulation of inclusions known as Lewy bodies and Lewy neurites.
Manuel Flores‐León, Tiago F. Outeiro
wiley +1 more source
Human Cyclophilins—An Emerging Class of Drug Targets
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova +3 more
wiley +1 more source
Research shows that (R, S)‐ketamine and its stereoisomers effectively reduce symptoms of post‐traumatic stress disorder (PTSD) and treatment‐resistant depression, with (R)‐ketamine offering similar benefits with fewer side effects. Evidence highlights specific neural circuits and regions, including the dentate gyrus, prefrontal cortex, vCA3, dorsal ...
Thomas Edward Cutting +1 more
wiley +1 more source

